We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.15 | 0.93% | 124.20 | 124.64 | 121.78 | 122.04 | 3,636,593 | 00:45:10 |
From May 2019 to May 2024
By Colin Kellaher
Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO, NVO) on Friday said they will collaborate on a clinical trial combining compounds from their pipelines in nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.
The companies said the trial will be a proof-of-concept study combining Novo's semaglutide and Gilead's cilofexor and firsocostat for the treatment of patients with NASH.
Gilead, a Foster City, Calif., biopharmaceutical company, and Danish pharmaceutical company Novo said they also may collaborate on preclinical research to advance understanding of the disease, which often affects people with diabetes and metabolic syndrome.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 12, 2019 06:25 ET (10:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
